Warren-based GlaxoSmithKline announced on Monday the U.S. Food and Drug Administration (FDA) approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1 percent arthritis pain reliever) as an ...

This drug has boxed warnings. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). It alerts doctors and patients about drug effects that may be dangerous.

First US approval for a prescription NSAID (non-steroidal anti-inflammatory drug) treatment that can be applied directly to site of osteoarthritis pain Voltaren Gel is the only prescription topical ...

FDA-Approved Product Is the First Prescription NSAID (Nonsteroidal Anti-Inflammatory Drug) That Patients Can Apply Directly to the Skin at the Site of Pain Associated With Osteoarthritis; Voltaren Gel ...

Novartis Corporation Voltaren Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis PARSIPPANY, N.J., Oct. 22 -- Voltaren(R) ...

Arthritis, a debilitating disease affecting millions worldwide, causes joint pain, inflammation, and rigidity, which can impair a person’s movement and everyday routine. Even though there are numerous ...

WARREN, N.J., May 3, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK), the makers of Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1%) today revealed new data that uncovers a ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store brand ...

WARREN, N.J., Feb. 17, 2020 /PRNewswire/ -- GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium ...